Evidence map›Paper›PMID 42528277›Full record

ReviewBrain and behavior2026

Epigenetic Mechanisms Underlying Cognitive Dysfunction in Parkinson's Disease: Current Evidence and Future Prospects.

Fatemeh Hasani, Mohammad Ebrahim Kherad, Mohammad Sharifi Sarasyabi, Kimia Jazi, Ali Ashkbari, Payam Ahmadi, Hadise Heidarpour, Mahdi Masrour, Sina Khamaki, Rahem Rahmati and 1 more

Abstract readReview
In one paragraph

Review in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fatemeh HasaniNeuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mohammad Ebrahim KheradGastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mohammad Sharifi SarasyabiSchool of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Kimia JaziSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali AshkbariNeuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Payam AhmadiFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hadise HeidarpourNeuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mahdi MasrourSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sina KhamakiNeuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Rahem RahmatiStudents Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Andrei SurguchovDepartment of Neurology, Kansas University Medical Center, Kansas City, Kansas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEpigenetics studies inheritable characteristics and lasting cellular changes that occur without alterations in the DNA sequence. This field is crucial for understanding how environmental factors interact with genes to influence memory, learning, and cognition. In the context of neurodegenerative disorders, particularly Parkinson's disease (PD), epigenetic mechanisms may help explain the molecular basis of cognitive impairment. The purpose of this review is to explore how epigenetic alterations affect gene expression and their potential role in cognitive dysfunction associated with PD.

methodThis review synthesizes findings from existing literature on epigenetic mechanisms-including microRNA (miRNA) regulation, histone modification, and DNA methylation-in relation to neuronal function and cognitive processes in PD. Relevant studies were identified and analyzed to determine how these mechanisms may contribute to neuroinflammation, synaptic remodeling, and neuroprotection in PD.

findingsEpigenetic modifications can activate or silence gene expression by altering chromatin structure and protein interactions without changing the DNA sequence. In PD, such changes may influence genes involved in neuroinflammation, neuronal plasticity, and protective signaling pathways. Evidence suggests that dysregulation of DNA methylation, histone modification, and miRNA expression could be linked to the cognitive deficits observed in PD patients. However, the current body of research remains limited and heterogeneous.

conclusionEpigenetic regulation represents a promising frontier for understanding cognitive impairment in PD. These mechanisms offer insights into how environmental and molecular factors interact to drive neurodegeneration. Further studies are needed to clarify the specific epigenetic alterations involved and to determine their potential as biomarkers or therapeutic targets for cognitive dysfunction in PD.

Indexed as

Cognitive DysfunctionEpigenesis, GeneticParkinson DiseaseAnimalsDNA MethylationHumansMicroRNAsMicroRNAsalpha‐synucleincognitionDNA methylationepigeneticsmiRNAParkinson's disease

Identifiers

PMID42528277
PMCPMC13420261

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.